Lck is a key target of imatinib and dasatinib in T-cell activation

Leukemia. 2010 Apr;24(4):896-900. doi: 10.1038/leu.2010.11. Epub 2010 Feb 11.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Benzamides
  • Blotting, Western
  • COS Cells
  • Chlorocebus aethiops
  • Dasatinib
  • Flow Cytometry
  • Green Fluorescent Proteins / genetics
  • Green Fluorescent Proteins / metabolism
  • Humans
  • Imatinib Mesylate
  • Immunoprecipitation
  • Lymphocyte Activation
  • Lymphocyte Specific Protein Tyrosine Kinase p56(lck) / antagonists & inhibitors*
  • Lymphocyte Specific Protein Tyrosine Kinase p56(lck) / genetics
  • Lymphocyte Specific Protein Tyrosine Kinase p56(lck) / metabolism
  • Phosphorylation / drug effects
  • Piperazines / pharmacology*
  • Protein Kinase Inhibitors / pharmacology*
  • Proto-Oncogene Proteins c-fyn / genetics
  • Proto-Oncogene Proteins c-fyn / metabolism
  • Pyrimidines / pharmacology*
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Reverse Transcriptase Polymerase Chain Reaction
  • T-Lymphocytes / drug effects*
  • Thiazoles / pharmacology*
  • src-Family Kinases / genetics
  • src-Family Kinases / metabolism

Substances

  • Benzamides
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • RNA, Messenger
  • Thiazoles
  • enhanced green fluorescent protein
  • Green Fluorescent Proteins
  • Imatinib Mesylate
  • FYN protein, human
  • Lymphocyte Specific Protein Tyrosine Kinase p56(lck)
  • Proto-Oncogene Proteins c-fyn
  • src-Family Kinases
  • Dasatinib